Research has found that taking adalimumab plus methotrexate is effective for patients with juvenile idiopathic arthritis-associated uveitis. However, these patients may also experience an increased incidence of adverse and serious adverse events compared with those taking only methotrexate…
In a clinical trial of pediatric patients, tocilizumab proved safe and effective for treating systemic juvenile idiopathic arthritis…
Through the use of large-scale transcriptome analysis, researchers have gained insight into the role of innate immunity in juvenile idiopathic arthritis (JIA) pathology. Specifically, transcriptomes of neutrophils in chronic inflammatory states demonstrate extensive network rewiring caused by microRNA, suggesting a role for alternative splicing in JIA pathogenesis…
Recent research has helped further define genetic heritability for pediatric autoimmune diseases. In an interview, Dr. Hakon Hakanarson discusses how understanding common genetic factors can help develop risk prediction and treatments for such diseases as juvenile idiopathic arthritis, lupus and celiac disease…
In a large group genetic analysis, researchers identified an association between the class II HLA region, including HLA-DRB1*11, and systemic juvenile idiopathic arthritis (sJIA), implicating adaptive immune molecules in sJIA’s pathogenesis and reinforcing its unique genetic position among JIA subtypes…
A pediatric rheumatologist faces continuity of care issues for a patient with systemic juvenile idiopathic arthritis whose parents are disruptive to the medical practice
Guidelines address advances in pathophysiology and treatment of systemic juvenile idiopathic arthritis; criteria classify broader spectrum of systemic sclerosis
A new study confirms that the use of immunosuppressive drugs is associated with a reduced risk of vision loss in patients with juvenile idiopathic arthritis-related uveitis.
How to encourage physical activity and exercise in juvenile idiopathic arthritis
Experts provided an in-depth review of Janus kinase (JAK) inhibitors, discussing the latest research on their use in the treatment of specific rheumatic conditions, the risks associated with them and more.